IMS and Virtify Partner to Deliver Enterprise Content Compliance Solutions to the European Marketplace
Virtify, Inc. and IMS Health (NYSE: RX) have partnered to jointly deliver Enterprise Content Compliance (ECC) solutions to the European marketplace.
The partnership will combine Virtify’s Virtx ECC Software Suite with comprehensive IMS services to help client companies manage regulated content and compliance issues throughout the product continuum. Virtify’s integrated software suite is an XML-based platform for structured content management, global labeling, submissions, and clinical trial disclosure that enables life sciences customers to reduce costs, mitigate risk and accelerate time to peak sales. Together, IMS and Virtify are uniquely qualified to service the needs of life sciences companies, through a combination of industry expertise, solutions, and comprehensive services. With over 50 years of dedicated life sciences experience, the partnership offers:
• Integrated business process consulting, technology, and services delivery
• Scalable structured content management
• Compliant labeling, submissions, and clinical trial disclosure solutions
• 3,000 customers worldwide
• Global presence
According to industry analyst firm IDC, the cost of bringing a new drug to market ranges from $800 million to $1.2 billion with close to a quarter of these costs coming from the content requirements associated with working in a regulatory compliant environment. The Virtx ECC Software Suite is engineered to meet these specific needs in the highly regulated pharmaceutical, biotechnology, medical device, animal health and food sciences industries.
The integrated Virtx Software Suite provides a secure, collaborative online environment for managing and reusing regulated content. It enables customers to manage the processes of submissions, document creation and review, global labeling, clinical trial disclosure and other regulatory management activities from a single platform.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
